Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT06193486

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 23 times

Summary

This early-phase trial tests a new treatment for men with advanced prostate cancer that has spread to the bone and no longer responds to standard therapies. The treatment involves taking a patient's own immune cells (gamma delta T cells), modifying them in a lab to better recognize and attack cancer cells, and infusing them back into the patient. The main goals are to find the safest dose and see if the treatment can shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER